Skip to main content

Drug Interactions between cyclophosphamide and interferon alfa-2b / ribavirin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

cycloPHOSphamide interferon alfa-2b

Applies to: cyclophosphamide and interferon alfa-2b / ribavirin

Human lymphoblastoid interferon has been shown to enhance the antitumor activity of doxorubicin and cyclophosphamide in animal models by delaying the G2 cell division phase and increasing the number of cells in the S phase. The clinical significance of this finding is unknown.

References (2)
  1. Balkwill FR, Mowshowitz S, Seilman SS, et al. (1984) "Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes." Cancer Res, 44, p. 5249-55
  2. Kang Y, Perry RR (1993) "Modulatory effects of tamoxifen and recombinant human alpha- interferon on doxorubicin resistance." Cancer Res, 53, p. 3040-5

Drug and food interactions

Moderate

ribavirin food

Applies to: interferon alfa-2b / ribavirin

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.

MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.

References (2)
  1. (2003) "Product Information. Copegus (ribavirin)." Roche Laboratories
  2. (2004) "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer